Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Downloadable slides from Clinical Care Options (CCO) with key takeaway points on newly approved agents for multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: February 2, 2021

Downloadable slides from Clinical Care Options (CCO) with nurse expert’s insights on available treatments, new approvals, and adverse event managements in patients with multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: January 28, 2021